Cellular and T cell engager Immunotherapy
Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy
Katja Weisel, MD (she/her/hers)
Deputy Director
University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
Hamburg, Germany